GleamWall
中文EN

BIIB BIOGEN INC.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 875045 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY2.3%
TTM net income YoY-78.4%
TTM EPS YoY-78.9%
Revenue 3-yr CAGR1.0%
Net income 3-yr CAGR-38.1%

Margins

Gross margin74.0%
Operating margin—
Net margin3.4%
FCF margin20.1%
EBITDA margin—

Returns

ROE1.9%
ROA1.1%
ROIC (approx.)—
Asset turnover0.34x

Leverage & solvency

Liabilities / assets41.0%
Debt / equity0.39x
Current ratio1.95x
Interest coverage—

Cash quality & payout

Operating cash flow / net income6.47x
Accruals ratio-6.2%
Payout ratio—
Capex / revenue1.7%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$9.89B$9.68B
Cost of revenue$2.40B$2.31B
Gross profit$7.49B$7.37B
R&D expense$1.78B$1.98B
SG&A expense$2.43B$2.40B
Interest expense$267.50M$250.30M
Pretax income$1.56B$1.91B
Income tax$263.60M$273.80M
Net income$1.29B$1.63B
EPS (basic)8.8311.21
EPS (diluted)8.7911.18
Weighted avg. shares (diluted)147.10M145.90M
Balance sheet
Cash & equivalents$3.01B$2.38B
Short-term investments$807.20M$0
Receivables$1.34B$1.40B
Inventory$2.17B$2.46B
Current assets$8.97B$7.46B
PP&E, net$3.06B$3.18B
Goodwill$6.49B$6.48B
Intangibles$9.18B$9.69B
Total assets$29.44B$28.05B
Current liabilities$3.35B$5.53B
Short-term debt$0$1.75B
Long-term debt$6.29B$4.55B
Total debt$6.29B$6.30B
Total liabilities$11.18B$11.33B
Shareholders' equity$18.26B$16.72B
Net debt$3.28B$3.92B
Shares outstanding146.80M145.80M
Cash flow statement
Operating cash flow$2.20B$2.88B
Capital expenditure$153.80M$153.70M
Free cash flow$2.05B$2.72B
Investing cash flow-$1.37B-$799.20M
Financing cash flow-$301.90M-$683.50M
Depreciation & amortization$779.90M$673.20M
Stock-based compensation$290.80M$291.20M
Share buybacks—$0

Free plan shows the latest 2 periods; Pro shows all 19 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.